Ty Kiser
Concepts (447)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anticoagulants | 13 | 2022 | 724 | 2.540 |
Why?
| | Venous Thromboembolism | 6 | 2025 | 324 | 2.440 |
Why?
| | Teicoplanin | 3 | 2024 | 14 | 2.150 |
Why?
| | Anti-Bacterial Agents | 15 | 2024 | 1915 | 2.110 |
Why?
| | Heparin | 10 | 2019 | 244 | 1.940 |
Why?
| | Vancomycin | 6 | 2024 | 93 | 1.840 |
Why?
| | Thrombocytopenia | 9 | 2020 | 205 | 1.800 |
Why?
| | Hirudins | 8 | 2020 | 51 | 1.750 |
Why?
| | Critical Illness | 21 | 2025 | 892 | 1.720 |
Why?
| | Factor Xa Inhibitors | 3 | 2025 | 187 | 1.690 |
Why?
| | Voriconazole | 3 | 2019 | 21 | 1.550 |
Why?
| | Intensive Care Units | 22 | 2025 | 916 | 1.510 |
Why?
| | Peptide Fragments | 7 | 2020 | 699 | 1.480 |
Why?
| | Triazoles | 3 | 2019 | 184 | 1.400 |
Why?
| | Antithrombins | 4 | 2020 | 70 | 1.400 |
Why?
| | Peritonitis | 2 | 2024 | 84 | 1.390 |
Why?
| | Antifungal Agents | 5 | 2025 | 149 | 1.330 |
Why?
| | Peritoneal Dialysis | 2 | 2024 | 100 | 1.300 |
Why?
| | Hemofiltration | 4 | 2017 | 24 | 1.250 |
Why?
| | Drug Packaging | 3 | 2016 | 41 | 1.210 |
Why?
| | Thrombin | 3 | 2020 | 166 | 1.190 |
Why?
| | Thrombosis | 4 | 2021 | 393 | 1.160 |
Why?
| | Drug Compounding | 3 | 2026 | 107 | 1.150 |
Why?
| | Pipecolic Acids | 4 | 2020 | 24 | 1.050 |
Why?
| | Thromboembolism | 3 | 2021 | 125 | 1.040 |
Why?
| | Critical Care | 11 | 2024 | 697 | 1.030 |
Why?
| | Fibrinolytic Agents | 4 | 2018 | 292 | 1.020 |
Why?
| | Hypnotics and Sedatives | 7 | 2025 | 216 | 1.010 |
Why?
| | Rivaroxaban | 3 | 2025 | 267 | 0.990 |
Why?
| | Tissue Plasminogen Activator | 2 | 2018 | 244 | 0.990 |
Why?
| | Invasive Fungal Infections | 3 | 2025 | 11 | 0.980 |
Why?
| | Microbial Sensitivity Tests | 6 | 2021 | 371 | 0.980 |
Why?
| | Pulmonary Embolism | 3 | 2019 | 244 | 0.980 |
Why?
| | Thiamine | 1 | 2026 | 18 | 0.960 |
Why?
| | Hospitalization | 9 | 2025 | 2434 | 0.950 |
Why?
| | Middle Aged | 56 | 2026 | 35928 | 0.920 |
Why?
| | Pharmacists | 5 | 2024 | 240 | 0.910 |
Why?
| | Kidney Diseases | 5 | 2021 | 427 | 0.890 |
Why?
| | beta-Cyclodextrins | 2 | 2015 | 32 | 0.890 |
Why?
| | Retrospective Studies | 39 | 2026 | 17101 | 0.860 |
Why?
| | Aged | 41 | 2026 | 25947 | 0.840 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 3 | 2019 | 923 | 0.840 |
Why?
| | Pharmacy Service, Hospital | 2 | 2024 | 81 | 0.820 |
Why?
| | Syringes | 3 | 2016 | 49 | 0.790 |
Why?
| | Humans | 100 | 2026 | 144957 | 0.780 |
Why?
| | Professional Role | 1 | 2024 | 158 | 0.770 |
Why?
| | Renal Replacement Therapy | 4 | 2022 | 100 | 0.770 |
Why?
| | Factor Xa | 2 | 2021 | 35 | 0.750 |
Why?
| | Hospital Mortality | 7 | 2025 | 1031 | 0.730 |
Why?
| | Dalteparin | 2 | 2020 | 10 | 0.730 |
Why?
| | Drug Stability | 4 | 2016 | 164 | 0.720 |
Why?
| | Nephrologists | 1 | 2021 | 14 | 0.690 |
Why?
| | Partial Thromboplastin Time | 5 | 2014 | 50 | 0.690 |
Why?
| | Gram-Positive Bacterial Infections | 2 | 2020 | 70 | 0.690 |
Why?
| | Recombinant Proteins | 10 | 2021 | 1371 | 0.690 |
Why?
| | Adrenal Cortex Hormones | 2 | 2015 | 479 | 0.680 |
Why?
| | Infusions, Intravenous | 7 | 2026 | 423 | 0.680 |
Why?
| | Adult | 42 | 2025 | 40506 | 0.670 |
Why?
| | Male | 59 | 2026 | 72406 | 0.670 |
Why?
| | Female | 59 | 2026 | 78376 | 0.670 |
Why?
| | Blood Coagulation Tests | 3 | 2016 | 70 | 0.650 |
Why?
| | Dose-Response Relationship, Drug | 11 | 2019 | 2032 | 0.620 |
Why?
| | Gram-Positive Bacteria | 1 | 2020 | 47 | 0.620 |
Why?
| | Pseudomonas Infections | 2 | 2013 | 221 | 0.610 |
Why?
| | Extravasation of Diagnostic and Therapeutic Materials | 2 | 2023 | 19 | 0.600 |
Why?
| | Drug Monitoring | 4 | 2017 | 395 | 0.600 |
Why?
| | Kidney Failure, Chronic | 3 | 2020 | 598 | 0.600 |
Why?
| | Antiviral Agents | 3 | 2020 | 768 | 0.580 |
Why?
| | Atrial Fibrillation | 2 | 2022 | 550 | 0.580 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2021 | 199 | 0.570 |
Why?
| | Heparin, Low-Molecular-Weight | 1 | 2018 | 36 | 0.570 |
Why?
| | Macrolides | 1 | 2019 | 69 | 0.570 |
Why?
| | Diabetic Ketoacidosis | 1 | 2021 | 210 | 0.550 |
Why?
| | Dexmedetomidine | 4 | 2014 | 44 | 0.550 |
Why?
| | Obesity, Morbid | 1 | 2022 | 281 | 0.550 |
Why?
| | Pulmonary Ventilation | 1 | 2018 | 83 | 0.540 |
Why?
| | Cold Temperature | 2 | 2016 | 209 | 0.540 |
Why?
| | Nitriles | 1 | 2019 | 205 | 0.530 |
Why?
| | Hepatorenal Syndrome | 2 | 2009 | 15 | 0.530 |
Why?
| | Glomerular Filtration Rate | 1 | 2021 | 760 | 0.520 |
Why?
| | Ribavirin | 2 | 2020 | 80 | 0.520 |
Why?
| | Piracetam | 1 | 2017 | 14 | 0.520 |
Why?
| | Anticonvulsants | 2 | 2017 | 242 | 0.520 |
Why?
| | Hemorrhage | 6 | 2022 | 809 | 0.510 |
Why?
| | Blood Transfusion | 2 | 2020 | 405 | 0.500 |
Why?
| | Aged, 80 and over | 14 | 2025 | 8279 | 0.500 |
Why?
| | Academic Medical Centers | 4 | 2026 | 548 | 0.500 |
Why?
| | Treatment Outcome | 20 | 2025 | 11695 | 0.500 |
Why?
| | Glass | 1 | 2016 | 46 | 0.490 |
Why?
| | Nitroprusside | 1 | 2016 | 72 | 0.490 |
Why?
| | Thiocyanates | 1 | 2016 | 28 | 0.490 |
Why?
| | Thiosulfates | 1 | 2016 | 19 | 0.490 |
Why?
| | Intracranial Hemorrhages | 1 | 2017 | 100 | 0.490 |
Why?
| | Lung Transplantation | 3 | 2020 | 338 | 0.480 |
Why?
| | Freezing | 1 | 2016 | 86 | 0.480 |
Why?
| | Cyclodextrins | 1 | 2015 | 11 | 0.460 |
Why?
| | Cerebral Hemorrhage | 1 | 2016 | 120 | 0.450 |
Why?
| | Therapeutics | 1 | 2015 | 14 | 0.440 |
Why?
| | Vasodilator Agents | 2 | 2016 | 331 | 0.440 |
Why?
| | Cardiopulmonary Bypass | 2 | 2016 | 221 | 0.440 |
Why?
| | Neoplasms | 3 | 2020 | 2884 | 0.430 |
Why?
| | Curriculum | 2 | 2021 | 1060 | 0.430 |
Why?
| | Pyridines | 1 | 2019 | 605 | 0.430 |
Why?
| | Antidotes | 1 | 2016 | 145 | 0.430 |
Why?
| | Respiratory Insufficiency | 4 | 2024 | 326 | 0.420 |
Why?
| | Vasoconstriction | 2 | 2023 | 217 | 0.410 |
Why?
| | Kidney | 2 | 2021 | 1496 | 0.410 |
Why?
| | Methylprednisolone | 1 | 2014 | 64 | 0.410 |
Why?
| | Osmotic Pressure | 1 | 2014 | 39 | 0.410 |
Why?
| | Stroke | 2 | 2022 | 1258 | 0.410 |
Why?
| | Patient Admission | 2 | 2025 | 218 | 0.390 |
Why?
| | Dronabinol | 1 | 2016 | 247 | 0.390 |
Why?
| | Cohort Studies | 14 | 2021 | 5965 | 0.390 |
Why?
| | Multivariate Analysis | 5 | 2017 | 1540 | 0.360 |
Why?
| | Pneumonia, Bacterial | 1 | 2013 | 113 | 0.360 |
Why?
| | Arginine | 4 | 2020 | 262 | 0.360 |
Why?
| | Ganciclovir | 1 | 2012 | 53 | 0.360 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2016 | 439 | 0.360 |
Why?
| | Benzodiazepines | 3 | 2025 | 168 | 0.350 |
Why?
| | Administration, Oral | 4 | 2022 | 848 | 0.350 |
Why?
| | Noninvasive Ventilation | 2 | 2024 | 62 | 0.340 |
Why?
| | Pseudomonas aeruginosa | 2 | 2013 | 356 | 0.340 |
Why?
| | Prospective Studies | 9 | 2025 | 7997 | 0.340 |
Why?
| | Pharmacies | 2 | 2021 | 42 | 0.340 |
Why?
| | Pharmacy | 2 | 2021 | 33 | 0.340 |
Why?
| | Empirical Research | 1 | 2011 | 21 | 0.340 |
Why?
| | Substance Withdrawal Syndrome | 3 | 2022 | 188 | 0.330 |
Why?
| | Drug Resistance, Multiple | 1 | 2010 | 25 | 0.320 |
Why?
| | Nomograms | 1 | 2011 | 59 | 0.320 |
Why?
| | Acute Kidney Injury | 4 | 2018 | 866 | 0.310 |
Why?
| | Cytomegalovirus Infections | 1 | 2012 | 206 | 0.310 |
Why?
| | Neurosurgical Procedures | 2 | 2024 | 202 | 0.310 |
Why?
| | Midazolam | 2 | 2024 | 72 | 0.310 |
Why?
| | Sulfonamides | 4 | 2020 | 581 | 0.300 |
Why?
| | Neuromuscular Blockade | 2 | 2025 | 51 | 0.300 |
Why?
| | Time Factors | 7 | 2018 | 7183 | 0.290 |
Why?
| | Drug Therapy, Combination | 5 | 2021 | 1048 | 0.280 |
Why?
| | Students, Pharmacy | 2 | 2021 | 96 | 0.280 |
Why?
| | Propofol | 2 | 2025 | 85 | 0.280 |
Why?
| | Young Adult | 9 | 2025 | 14126 | 0.270 |
Why?
| | Thrombin Time | 2 | 2020 | 11 | 0.260 |
Why?
| | Daptomycin | 2 | 2021 | 18 | 0.260 |
Why?
| | Burns | 2 | 2018 | 377 | 0.260 |
Why?
| | Sympathomimetics | 1 | 2007 | 19 | 0.260 |
Why?
| | Polypropylenes | 1 | 2007 | 12 | 0.260 |
Why?
| | Phenylephrine | 1 | 2007 | 75 | 0.260 |
Why?
| | Expectorants | 1 | 2007 | 23 | 0.260 |
Why?
| | Administration, Intravenous | 3 | 2017 | 170 | 0.260 |
Why?
| | Patient Discharge | 3 | 2018 | 983 | 0.250 |
Why?
| | Shock, Septic | 2 | 2022 | 216 | 0.250 |
Why?
| | Pharmacoepidemiology | 2 | 2019 | 22 | 0.250 |
Why?
| | Drug Storage | 3 | 2016 | 53 | 0.250 |
Why?
| | Lorazepam | 3 | 2014 | 25 | 0.240 |
Why?
| | Ofloxacin | 1 | 2006 | 17 | 0.240 |
Why?
| | Levofloxacin | 1 | 2006 | 20 | 0.240 |
Why?
| | Acetylcysteine | 1 | 2007 | 139 | 0.240 |
Why?
| | Respiration | 1 | 2007 | 207 | 0.240 |
Why?
| | Substance-Related Disorders | 2 | 2025 | 1094 | 0.230 |
Why?
| | Gentamicins | 2 | 2023 | 51 | 0.230 |
Why?
| | Anesthetics | 1 | 2007 | 99 | 0.230 |
Why?
| | Alcoholism | 2 | 2023 | 817 | 0.230 |
Why?
| | Adolescent | 10 | 2025 | 22453 | 0.230 |
Why?
| | Models, Biological | 1 | 2013 | 1822 | 0.230 |
Why?
| | Area Under Curve | 4 | 2019 | 331 | 0.230 |
Why?
| | Arginine Vasopressin | 1 | 2005 | 44 | 0.230 |
Why?
| | Vasoconstrictor Agents | 2 | 2023 | 144 | 0.230 |
Why?
| | Octreotide | 1 | 2005 | 23 | 0.230 |
Why?
| | Costs and Cost Analysis | 1 | 2026 | 220 | 0.220 |
Why?
| | Pneumonia | 3 | 2023 | 631 | 0.220 |
Why?
| | Neuromuscular Blocking Agents | 2 | 2018 | 26 | 0.220 |
Why?
| | Cross-Over Studies | 2 | 2020 | 601 | 0.210 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2021 | 3890 | 0.210 |
Why?
| | Warfarin | 2 | 2022 | 170 | 0.200 |
Why?
| | Chromatography, High Pressure Liquid | 3 | 2024 | 598 | 0.200 |
Why?
| | Length of Stay | 4 | 2019 | 1337 | 0.200 |
Why?
| | Hydrogen-Ion Concentration | 2 | 2016 | 561 | 0.200 |
Why?
| | Temperature | 3 | 2016 | 679 | 0.200 |
Why?
| | Blood Coagulation | 2 | 2016 | 268 | 0.190 |
Why?
| | Saline Solution, Hypertonic | 1 | 2023 | 42 | 0.190 |
Why?
| | Liver Diseases | 1 | 2006 | 304 | 0.190 |
Why?
| | Ethanol | 3 | 2022 | 627 | 0.180 |
Why?
| | Incidence | 2 | 2020 | 2883 | 0.180 |
Why?
| | Liver Transplantation | 1 | 2009 | 823 | 0.180 |
Why?
| | Risk Factors | 7 | 2023 | 10792 | 0.180 |
Why?
| | Practice Patterns, Physicians' | 2 | 2025 | 1358 | 0.180 |
Why?
| | Thinness | 1 | 2022 | 99 | 0.180 |
Why?
| | Sexual Harassment | 1 | 2021 | 29 | 0.170 |
Why?
| | Aspergillosis | 1 | 2021 | 23 | 0.170 |
Why?
| | Prothrombin | 1 | 2021 | 25 | 0.170 |
Why?
| | Statistics, Nonparametric | 3 | 2017 | 427 | 0.170 |
Why?
| | Candidiasis | 1 | 2021 | 64 | 0.170 |
Why?
| | Pharmaceutical Services | 1 | 2021 | 78 | 0.170 |
Why?
| | Community Pharmacy Services | 1 | 2021 | 46 | 0.170 |
Why?
| | Drug Administration Schedule | 3 | 2018 | 783 | 0.170 |
Why?
| | Cephalosporins | 1 | 2021 | 47 | 0.160 |
Why?
| | United States | 10 | 2025 | 15988 | 0.160 |
Why?
| | Ascitic Fluid | 1 | 2020 | 15 | 0.160 |
Why?
| | Vasoplegia | 1 | 2020 | 5 | 0.160 |
Why?
| | Salvage Therapy | 1 | 2021 | 162 | 0.150 |
Why?
| | Platelet Count | 1 | 2020 | 96 | 0.150 |
Why?
| | Asthma | 2 | 2022 | 1768 | 0.150 |
Why?
| | Monte Carlo Method | 2 | 2013 | 155 | 0.150 |
Why?
| | Analgesics, Opioid | 2 | 2025 | 1143 | 0.150 |
Why?
| | Hydroxocobalamin | 1 | 2020 | 33 | 0.150 |
Why?
| | Speech Therapy | 1 | 2019 | 21 | 0.150 |
Why?
| | Anti-Infective Agents | 1 | 2022 | 242 | 0.150 |
Why?
| | Body Weight | 2 | 2021 | 978 | 0.150 |
Why?
| | Respiratory Syncytial Virus Infections | 1 | 2020 | 136 | 0.140 |
Why?
| | Tandem Mass Spectrometry | 2 | 2024 | 577 | 0.140 |
Why?
| | Vecuronium Bromide | 1 | 2018 | 7 | 0.140 |
Why?
| | Atracurium | 1 | 2018 | 14 | 0.140 |
Why?
| | Heart Failure, Diastolic | 1 | 2018 | 24 | 0.140 |
Why?
| | Gastric Emptying | 2 | 2008 | 36 | 0.140 |
Why?
| | Calcineurin Inhibitors | 1 | 2018 | 69 | 0.140 |
Why?
| | Hemostasis | 1 | 2019 | 102 | 0.140 |
Why?
| | Heart Failure, Systolic | 1 | 2018 | 27 | 0.140 |
Why?
| | Coronary Circulation | 1 | 2018 | 136 | 0.140 |
Why?
| | Extracorporeal Membrane Oxygenation | 1 | 2022 | 383 | 0.140 |
Why?
| | Cardiologists | 1 | 2018 | 47 | 0.140 |
Why?
| | Logistic Models | 3 | 2017 | 2119 | 0.130 |
Why?
| | Kidney Transplantation | 2 | 2018 | 704 | 0.130 |
Why?
| | Intubation, Intratracheal | 1 | 2020 | 320 | 0.130 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2021 | 249 | 0.130 |
Why?
| | Gastrointestinal Agents | 2 | 2008 | 66 | 0.130 |
Why?
| | Comparative Effectiveness Research | 1 | 2018 | 170 | 0.130 |
Why?
| | Education, Pharmacy, Graduate | 1 | 2017 | 12 | 0.130 |
Why?
| | Antibodies, Bacterial | 1 | 2018 | 148 | 0.130 |
Why?
| | Polyneuropathies | 1 | 2017 | 57 | 0.130 |
Why?
| | Immunity, Humoral | 1 | 2018 | 120 | 0.130 |
Why?
| | Occupational Therapy | 1 | 2019 | 111 | 0.130 |
Why?
| | Self-Directed Learning as Topic | 1 | 2017 | 5 | 0.130 |
Why?
| | Pneumococcal Vaccines | 1 | 2018 | 130 | 0.130 |
Why?
| | Pharmaceutical Solutions | 1 | 2016 | 14 | 0.130 |
Why?
| | Chromatography, Reverse-Phase | 1 | 2016 | 27 | 0.120 |
Why?
| | Career Mobility | 1 | 2017 | 72 | 0.120 |
Why?
| | Disease-Free Survival | 1 | 2018 | 769 | 0.120 |
Why?
| | Capsules | 1 | 2016 | 43 | 0.120 |
Why?
| | Staphylococcal Infections | 1 | 2021 | 390 | 0.120 |
Why?
| | Transplant Recipients | 2 | 2018 | 180 | 0.120 |
Why?
| | Immunotherapy | 1 | 2021 | 657 | 0.120 |
Why?
| | Solubility | 1 | 2016 | 242 | 0.120 |
Why?
| | Patient Readmission | 2 | 2019 | 759 | 0.120 |
Why?
| | Propensity Score | 2 | 2017 | 367 | 0.120 |
Why?
| | Databases, Factual | 2 | 2019 | 1486 | 0.120 |
Why?
| | Cholestyramine Resin | 1 | 2015 | 5 | 0.120 |
Why?
| | Regression Analysis | 2 | 2016 | 1003 | 0.120 |
Why?
| | Psychotropic Drugs | 1 | 2016 | 77 | 0.120 |
Why?
| | Enteral Nutrition | 2 | 2008 | 216 | 0.120 |
Why?
| | Physical Therapy Modalities | 1 | 2019 | 332 | 0.120 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2019 | 279 | 0.110 |
Why?
| | Drug Prescriptions | 1 | 2018 | 285 | 0.110 |
Why?
| | Calibration | 1 | 2016 | 151 | 0.110 |
Why?
| | Pharmacokinetics | 1 | 2015 | 32 | 0.110 |
Why?
| | Isoxazoles | 1 | 2015 | 54 | 0.110 |
Why?
| | Societies, Pharmaceutical | 1 | 2015 | 14 | 0.110 |
Why?
| | Internship, Nonmedical | 1 | 2015 | 10 | 0.110 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2018 | 338 | 0.110 |
Why?
| | Administration, Inhalation | 1 | 2016 | 575 | 0.110 |
Why?
| | Ventricular Function, Left | 1 | 2018 | 541 | 0.110 |
Why?
| | Respiration, Artificial | 4 | 2025 | 708 | 0.110 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2021 | 988 | 0.110 |
Why?
| | Enterocolitis, Pseudomembranous | 1 | 2014 | 28 | 0.110 |
Why?
| | Anti-Ulcer Agents | 1 | 2014 | 12 | 0.110 |
Why?
| | Histamine H2 Antagonists | 1 | 2014 | 23 | 0.110 |
Why?
| | Prosthesis-Related Infections | 1 | 2015 | 99 | 0.110 |
Why?
| | Opioid-Related Disorders | 1 | 2023 | 601 | 0.110 |
Why?
| | Peptic Ulcer | 1 | 2014 | 18 | 0.110 |
Why?
| | Teaching | 1 | 2017 | 236 | 0.110 |
Why?
| | Double-Blind Method | 4 | 2014 | 2029 | 0.110 |
Why?
| | Diltiazem | 1 | 2014 | 17 | 0.110 |
Why?
| | Dabigatran | 1 | 2014 | 29 | 0.100 |
Why?
| | beta-Alanine | 1 | 2014 | 23 | 0.100 |
Why?
| | Pyridones | 1 | 2016 | 199 | 0.100 |
Why?
| | Thromboplastin | 1 | 2014 | 69 | 0.100 |
Why?
| | Drug Dosage Calculations | 1 | 2014 | 27 | 0.100 |
Why?
| | Proton Pump Inhibitors | 1 | 2014 | 109 | 0.100 |
Why?
| | Immunoglobulin G | 1 | 2018 | 893 | 0.100 |
Why?
| | Medication Adherence | 1 | 2018 | 539 | 0.100 |
Why?
| | Guidelines as Topic | 1 | 2015 | 268 | 0.100 |
Why?
| | Gastrointestinal Hemorrhage | 1 | 2014 | 136 | 0.100 |
Why?
| | Oxazolidinones | 1 | 2012 | 17 | 0.100 |
Why?
| | Seizures | 1 | 2017 | 477 | 0.100 |
Why?
| | Benzimidazoles | 1 | 2014 | 190 | 0.090 |
Why?
| | Antirheumatic Agents | 1 | 2015 | 304 | 0.090 |
Why?
| | APACHE | 2 | 2010 | 66 | 0.090 |
Why?
| | Antibiotic Prophylaxis | 1 | 2014 | 129 | 0.090 |
Why?
| | Acetamides | 1 | 2012 | 38 | 0.090 |
Why?
| | Community-Acquired Infections | 1 | 2014 | 174 | 0.090 |
Why?
| | Learning | 1 | 2017 | 452 | 0.090 |
Why?
| | Motivation | 1 | 2017 | 610 | 0.090 |
Why?
| | Sirolimus | 1 | 2014 | 281 | 0.090 |
Why?
| | Treatment Failure | 1 | 2013 | 365 | 0.090 |
Why?
| | Patient Acceptance of Health Care | 1 | 2019 | 886 | 0.090 |
Why?
| | Colorado | 3 | 2017 | 4564 | 0.090 |
Why?
| | Metabolic Clearance Rate | 1 | 2012 | 115 | 0.090 |
Why?
| | Patient Selection | 1 | 2016 | 719 | 0.090 |
Why?
| | Acute Disease | 1 | 2015 | 1031 | 0.090 |
Why?
| | Pyrazoles | 1 | 2016 | 510 | 0.090 |
Why?
| | Mental Recall | 1 | 2013 | 222 | 0.090 |
Why?
| | Injections, Intravenous | 1 | 2012 | 200 | 0.090 |
Why?
| | Metoclopramide | 2 | 2008 | 19 | 0.090 |
Why?
| | Erythromycin | 2 | 2008 | 20 | 0.090 |
Why?
| | Coronary Artery Bypass | 1 | 2014 | 269 | 0.090 |
Why?
| | Research | 1 | 2015 | 431 | 0.090 |
Why?
| | Polymorphism, Genetic | 1 | 2014 | 612 | 0.080 |
Why?
| | Heart Valve Prosthesis Implantation | 1 | 2014 | 197 | 0.080 |
Why?
| | Disease Progression | 2 | 2020 | 2852 | 0.080 |
Why?
| | Lipids | 1 | 2016 | 710 | 0.080 |
Why?
| | Fellowships and Scholarships | 1 | 2015 | 357 | 0.080 |
Why?
| | Aortic Valve | 1 | 2014 | 365 | 0.080 |
Why?
| | Glucocorticoids | 1 | 2015 | 535 | 0.080 |
Why?
| | Surgical Wound Infection | 1 | 2014 | 316 | 0.080 |
Why?
| | Imipenem | 1 | 2010 | 16 | 0.080 |
Why?
| | Genes, Regulator | 1 | 2010 | 35 | 0.080 |
Why?
| | Anti-Inflammatory Agents | 1 | 2014 | 475 | 0.080 |
Why?
| | Drug Resistance | 1 | 2011 | 153 | 0.080 |
Why?
| | Pharmaceutical Vehicles | 1 | 2009 | 12 | 0.080 |
Why?
| | Propylene Glycol | 1 | 2009 | 9 | 0.080 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2010 | 331 | 0.080 |
Why?
| | Hypothermia, Induced | 1 | 2011 | 96 | 0.080 |
Why?
| | Protein C | 1 | 2010 | 53 | 0.080 |
Why?
| | Risk Assessment | 2 | 2016 | 3676 | 0.070 |
Why?
| | Portasystemic Shunt, Transjugular Intrahepatic | 1 | 2009 | 38 | 0.070 |
Why?
| | Biomedical Research | 1 | 2015 | 710 | 0.070 |
Why?
| | Monitoring, Physiologic | 1 | 2010 | 289 | 0.070 |
Why?
| | Acetaminophen | 2 | 2008 | 264 | 0.070 |
Why?
| | Sensitivity and Specificity | 1 | 2013 | 1990 | 0.070 |
Why?
| | Prevalence | 2 | 2025 | 2836 | 0.070 |
Why?
| | Kidney Function Tests | 1 | 2008 | 157 | 0.070 |
Why?
| | Aging | 1 | 2019 | 1966 | 0.070 |
Why?
| | Certification | 1 | 2009 | 119 | 0.070 |
Why?
| | Standard of Care | 2 | 2021 | 80 | 0.070 |
Why?
| | Biomarkers | 2 | 2016 | 4275 | 0.060 |
Why?
| | Cost Control | 1 | 2007 | 37 | 0.060 |
Why?
| | Liver Cirrhosis | 1 | 2009 | 288 | 0.060 |
Why?
| | Lung Diseases | 1 | 2014 | 787 | 0.060 |
Why?
| | Databases as Topic | 1 | 2007 | 71 | 0.060 |
Why?
| | Infant, Newborn | 1 | 2019 | 6434 | 0.060 |
Why?
| | Creatinine | 1 | 2008 | 506 | 0.060 |
Why?
| | Analgesics, Non-Narcotic | 1 | 2008 | 124 | 0.060 |
Why?
| | Renal Dialysis | 1 | 2010 | 462 | 0.060 |
Why?
| | Half-Life | 1 | 2006 | 151 | 0.060 |
Why?
| | Schools, Pharmacy | 2 | 2017 | 47 | 0.060 |
Why?
| | Emergency Service, Hospital | 1 | 2018 | 2313 | 0.060 |
Why?
| | Antidiuretic Agents | 1 | 2005 | 5 | 0.060 |
Why?
| | Fentanyl | 1 | 2007 | 127 | 0.060 |
Why?
| | Platelet Aggregation | 1 | 2005 | 105 | 0.060 |
Why?
| | Platelet Activation | 1 | 2005 | 104 | 0.060 |
Why?
| | Chromatography, Liquid | 1 | 2007 | 454 | 0.060 |
Why?
| | Severity of Illness Index | 1 | 2013 | 2925 | 0.060 |
Why?
| | Gene Expression Regulation | 1 | 2014 | 2609 | 0.050 |
Why?
| | Practice Guidelines as Topic | 1 | 2012 | 1563 | 0.050 |
Why?
| | DNA | 1 | 2010 | 1464 | 0.050 |
Why?
| | Analgesia | 1 | 2024 | 105 | 0.050 |
Why?
| | Penicillins | 1 | 2023 | 61 | 0.050 |
Why?
| | Animals | 2 | 2016 | 38109 | 0.050 |
Why?
| | Transcription Factors | 1 | 2010 | 1742 | 0.040 |
Why?
| | Minnesota | 1 | 2022 | 169 | 0.040 |
Why?
| | Vasopressins | 1 | 2022 | 60 | 0.040 |
Why?
| | Computer Simulation | 1 | 2006 | 1026 | 0.040 |
Why?
| | Norepinephrine | 1 | 2022 | 196 | 0.040 |
Why?
| | Serum Albumin | 1 | 2022 | 147 | 0.040 |
Why?
| | Critical Care Outcomes | 1 | 2020 | 11 | 0.040 |
Why?
| | Status Asthmaticus | 1 | 2020 | 13 | 0.040 |
Why?
| | Gender Identity | 1 | 2021 | 121 | 0.040 |
Why?
| | Rifampin | 1 | 2021 | 82 | 0.040 |
Why?
| | Polyphosphates | 1 | 2020 | 45 | 0.040 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2023 | 257 | 0.040 |
Why?
| | Rural Population | 1 | 2025 | 650 | 0.040 |
Why?
| | Hypertension, Pulmonary | 1 | 2012 | 1980 | 0.040 |
Why?
| | Hypersensitivity | 1 | 2023 | 252 | 0.040 |
Why?
| | Methylene Blue | 1 | 2020 | 24 | 0.040 |
Why?
| | Drug Synergism | 1 | 2021 | 357 | 0.040 |
Why?
| | Sepsis | 2 | 2020 | 641 | 0.040 |
Why?
| | Surveys and Questionnaires | 3 | 2021 | 6053 | 0.040 |
Why?
| | Mutation | 1 | 2010 | 4099 | 0.040 |
Why?
| | Interprofessional Relations | 1 | 2021 | 281 | 0.040 |
Why?
| | Pilot Projects | 2 | 2015 | 1890 | 0.040 |
Why?
| | Vascular Resistance | 1 | 2020 | 367 | 0.040 |
Why?
| | Bacteremia | 1 | 2021 | 221 | 0.030 |
Why?
| | Sex Factors | 2 | 2018 | 2114 | 0.030 |
Why?
| | Hospitals, Rural | 1 | 2018 | 51 | 0.030 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2020 | 636 | 0.030 |
Why?
| | Patient Satisfaction | 1 | 2022 | 705 | 0.030 |
Why?
| | Hospital Charges | 1 | 2017 | 46 | 0.030 |
Why?
| | Hospitals, Urban | 1 | 2018 | 144 | 0.030 |
Why?
| | Muscular Diseases | 1 | 2017 | 108 | 0.030 |
Why?
| | Bayes Theorem | 1 | 2019 | 433 | 0.030 |
Why?
| | Drug Interactions | 1 | 2018 | 401 | 0.030 |
Why?
| | Venous Thrombosis | 1 | 2019 | 195 | 0.030 |
Why?
| | Insurance Coverage | 1 | 2018 | 239 | 0.030 |
Why?
| | Problem-Based Learning | 1 | 2017 | 98 | 0.030 |
Why?
| | Comorbidity | 1 | 2020 | 1660 | 0.030 |
Why?
| | Pharmacology, Clinical | 1 | 2015 | 9 | 0.030 |
Why?
| | Risk | 1 | 2018 | 911 | 0.030 |
Why?
| | Education, Pharmacy | 1 | 2017 | 121 | 0.030 |
Why?
| | Expert Testimony | 1 | 2015 | 42 | 0.030 |
Why?
| | Peptic Ulcer Hemorrhage | 1 | 2014 | 5 | 0.030 |
Why?
| | Cytochrome P-450 CYP2C8 | 1 | 2014 | 14 | 0.030 |
Why?
| | Checklist | 1 | 2015 | 108 | 0.030 |
Why?
| | Bradycardia | 1 | 2014 | 59 | 0.030 |
Why?
| | Infusions, Parenteral | 1 | 2014 | 41 | 0.030 |
Why?
| | Receptors, Steroid | 1 | 2014 | 45 | 0.030 |
Why?
| | Aryl Hydrocarbon Hydroxylases | 1 | 2014 | 45 | 0.030 |
Why?
| | Stress Disorders, Traumatic, Acute | 1 | 2013 | 7 | 0.030 |
Why?
| | Everolimus | 1 | 2014 | 111 | 0.030 |
Why?
| | Educational Measurement | 1 | 2017 | 326 | 0.030 |
Why?
| | Hypotension | 1 | 2014 | 126 | 0.020 |
Why?
| | Tissue Distribution | 1 | 2014 | 334 | 0.020 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 2014 | 93 | 0.020 |
Why?
| | Delphi Technique | 1 | 2015 | 331 | 0.020 |
Why?
| | Demography | 1 | 2014 | 288 | 0.020 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2014 | 421 | 0.020 |
Why?
| | Cerebral Ventriculitis | 1 | 2012 | 3 | 0.020 |
Why?
| | Vancomycin Resistance | 1 | 2012 | 16 | 0.020 |
Why?
| | Injections, Intraventricular | 1 | 2012 | 58 | 0.020 |
Why?
| | Linezolid | 1 | 2012 | 25 | 0.020 |
Why?
| | Enterococcus faecium | 1 | 2012 | 22 | 0.020 |
Why?
| | Health Care Surveys | 1 | 2014 | 539 | 0.020 |
Why?
| | Cross-Sectional Studies | 2 | 2014 | 5872 | 0.020 |
Why?
| | Drainage | 1 | 2012 | 185 | 0.020 |
Why?
| | Healthcare Disparities | 1 | 2018 | 728 | 0.020 |
Why?
| | Stress, Physiological | 1 | 2014 | 453 | 0.020 |
Why?
| | Contraindications | 1 | 2010 | 91 | 0.020 |
Why?
| | Governing Board | 1 | 2009 | 7 | 0.020 |
Why?
| | Immunosuppressive Agents | 1 | 2014 | 847 | 0.020 |
Why?
| | Multiple Organ Failure | 1 | 2010 | 124 | 0.020 |
Why?
| | Genotype | 1 | 2014 | 1835 | 0.020 |
Why?
| | Observer Variation | 1 | 2010 | 355 | 0.020 |
Why?
| | Diagnostic Errors | 1 | 2010 | 175 | 0.020 |
Why?
| | Quality of Life | 1 | 2021 | 3192 | 0.020 |
Why?
| | Dopamine Antagonists | 1 | 2008 | 25 | 0.020 |
Why?
| | Specialization | 1 | 2009 | 136 | 0.020 |
Why?
| | Data Interpretation, Statistical | 1 | 2010 | 372 | 0.020 |
Why?
| | Intubation, Gastrointestinal | 1 | 2008 | 82 | 0.020 |
Why?
| | Clinical Trials as Topic | 1 | 2012 | 1054 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2014 | 3608 | 0.020 |
Why?
| | Attitude of Health Personnel | 1 | 2014 | 1186 | 0.010 |
Why?
| | Anxiety | 1 | 2013 | 1110 | 0.010 |
Why?
| | Prognosis | 1 | 2014 | 4293 | 0.010 |
Why?
| | Follow-Up Studies | 1 | 2014 | 5417 | 0.010 |
Why?
| | Predictive Value of Tests | 1 | 2010 | 2118 | 0.010 |
Why?
| | Depression | 1 | 2013 | 1559 | 0.010 |
Why?
| | Age Factors | 1 | 2009 | 3335 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2010 | 3415 | 0.010 |
Why?
| | Physicians | 1 | 2010 | 940 | 0.010 |
Why?
| | Clinical Competence | 1 | 2009 | 1244 | 0.010 |
Why?
|
|
Kiser's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|